Longeveron announces positive Phase 2a top-line results for Lomecel-B in mild Alzheimer's disease

Longeveron Inc.

Primary safety endpoint met; one SAE per Lomecel-B group, none on placebo, DSMB no issues.
Secondary endpoint CADS showed statistical improvement for 25M single dose (p=0.091) and pooled groups (p=0.099) vs placebo at week 39.
Lomecel-B low-dose (25M x1) significantly slowed left hippocampal volume loss (p=0.015) vs placebo.
Pooled Lomecel-B groups showed significant improvement in ADCS-ADL (p=0.047) at week 39.
Webcast and conference call held Oct 5, 2023 at 8:00 AM ET to discuss results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.